Atlit

Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma

Retrieved on: 
Wednesday, November 15, 2023

The study safety profile demonstrated that FT011 was safe and well tolerated, with no differences in adverse event (AE) rates between the treatment arms.

Key Points: 
  • The study safety profile demonstrated that FT011 was safe and well tolerated, with no differences in adverse event (AE) rates between the treatment arms.
  • There were no serious AEs reported in the study, nor any AEs resulting in study drug interruption, withdrawal or discontinuation.
  • This suggests that FT011 may have a positive effect for scleroderma patients by reducing the inflammation and fibrosis associated with the disease.
  • It is important to advance safe and effective treatments through clinical development, given the limited therapeutic options for scleroderma patients.

Certa and Castellum.AI Partner to Provide Compliance and Procurement Professionals with Enhanced Financial Crime Risk Data for Improved Third-Party Risk Management

Retrieved on: 
Thursday, December 7, 2023

Certa , the leader in third-party management solutions, today announced a partnership with Castellum.AI , a global financial crime risk platform.

Key Points: 
  • Certa , the leader in third-party management solutions, today announced a partnership with Castellum.AI , a global financial crime risk platform.
  • Third-party risk management professionals often rely on multiple systems to maintain vendor onboarding, due diligence, investigations, and other aspects of their job.
  • By providing financial crime risk screening directly within their TPRM platform, Certa and Castellum.AI enable these professionals to automate the entire risk screening process.
  • “By integrating our data with Certa’s TPRM solution, we’re able to provide compliance and procurement professionals with the most accurate and reliable vendor risk insights, updated every five minutes.

Certa Appoints Natalie Druckmann as New VP of Sales, EMEA

Retrieved on: 
Thursday, November 30, 2023

Certa , the leader in third-party management solutions, today announced the appointment of Natalie Druckmann as VP of Sales, EMEA.

Key Points: 
  • Certa , the leader in third-party management solutions, today announced the appointment of Natalie Druckmann as VP of Sales, EMEA.
  • In the role, Natalie will be responsible for setting the strategy for expansion into the Europe, Middle East, and Africa markets, and growing the company’s customer base within those regions.
  • “Natalie has extensive experience in the TPRM field and has proven her ability to provide consistent, measurable, and target-driven results,” said Jag Lamba, CEO and founder of Certa.
  • “As we continue our expansion into EMEA, we are lucky to have a skilled sales leader like Natalie guiding our strategy.”
    Prior to joining Certa, Natalie spent the last three years leading the global Risk and Performance SME team for Coupa Software, supporting customers in their TPRM journey.

Certa Revolutionizes Third Party Management with CertaAssist, An Intuitive AI Companion For Faster, Simpler Third Party Interactions

Retrieved on: 
Thursday, October 26, 2023

Certa , the leader in third-party management solutions, today introduced CertaAssist, an intuitive AI companion powered by the advanced Certa AI.

Key Points: 
  • Certa , the leader in third-party management solutions, today introduced CertaAssist, an intuitive AI companion powered by the advanced Certa AI.
  • This groundbreaking launch merges advanced generative AI technology with third-party management, marking a new era in operational agility by offering AI-powered workflow optimization, intuitive data visualization, and streamlined supplier onboarding.
  • “Certa is the pioneer of third-party management solutions, striving to be a leader and innovator in the risk and compliance market.
  • By offering AI capabilities within our tool, we are providing our clients and their suppliers with cutting-edge solutions that enhance efficiency, accuracy, and security in third-party management,” said Jag Lamba, Certa founder & CEO.

Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis

Retrieved on: 
Monday, October 23, 2023

MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma).

Key Points: 
  • MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma).
  • "We are very pleased that the FDA has granted Orphan Drug Designation to FT011 which we believe highlights the urgent need for innovation and new therapeutic options for scleroderma patients" said Professor Darren Kelly, Certa Therapeutics CEO and founder.
  • U.S. Food and Drug Administration Orphan Drug Designation.
  • S Eddy, et al., "Identification of Non-Invasive Surrogates as Predictors of Response to FT011 in Kidney Disease" ASN Kidney Week 2022, abstract 3767783

Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis

Retrieved on: 
Monday, October 23, 2023

MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma).

Key Points: 
  • MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma).
  • "We are very pleased that the FDA has granted Orphan Drug Designation to FT011 which we believe highlights the urgent need for innovation and new therapeutic options for scleroderma patients" said Professor Darren Kelly, Certa Therapeutics CEO and founder.
  • U.S. Food and Drug Administration Orphan Drug Designation.
  • S Eddy, et al., "Identification of Non-Invasive Surrogates as Predictors of Response to FT011 in Kidney Disease" ASN Kidney Week 2022, abstract 3767783

Markel makes a strategic investment in leading tax MGA, Certa

Retrieved on: 
Friday, October 20, 2023

LONDON, Oct. 20, 2023 /PRNewswire/ -- Markel, the insurance operation within Markel Group Inc. (NYSE: MKL), today announces a 49% strategic investment in Certa, the market-leading tax MGA.

Key Points: 
  • LONDON, Oct. 20, 2023 /PRNewswire/ -- Markel, the insurance operation within Markel Group Inc. (NYSE: MKL), today announces a 49% strategic investment in Certa, the market-leading tax MGA.
  • Certa was formed in 2019 by four market professionals – Ed Beckwith, Tom Cartwright, Rachel Hine, and Adam Singer – to establish a dedicated tax underwriting MGA, with the support of Markel as one of its original capacity providers.
  • Since then, Certa has gone from strength-to-strength, creating the only underwriting agency focused exclusively on tax and contingent risk insurance, backed by 12 capacity providers.
  • As part of this investment, Markel will work closely with Certa's management team to support the MGA's business strategy.

Markel makes a strategic investment in leading tax MGA, Certa

Retrieved on: 
Friday, October 20, 2023

LONDON, Oct. 20, 2023 /PRNewswire/ -- Markel, the insurance operation within Markel Group Inc. (NYSE: MKL), today announces a 49% strategic investment in Certa, the market-leading tax MGA.

Key Points: 
  • LONDON, Oct. 20, 2023 /PRNewswire/ -- Markel, the insurance operation within Markel Group Inc. (NYSE: MKL), today announces a 49% strategic investment in Certa, the market-leading tax MGA.
  • Certa was formed in 2019 by four market professionals – Ed Beckwith, Tom Cartwright, Rachel Hine, and Adam Singer – to establish a dedicated tax underwriting MGA, with the support of Markel as one of its original capacity providers.
  • Since then, Certa has gone from strength-to-strength, creating the only underwriting agency focused exclusively on tax and contingent risk insurance, backed by 12 capacity providers.
  • As part of this investment, Markel will work closely with Certa's management team to support the MGA's business strategy.

Certa Hires First-Ever CRO Eric Brown Following Series B Funding

Retrieved on: 
Tuesday, September 12, 2023

The all-in-one third-party management platform, Certa , is pleased to announce the addition of Eric Brown as its first-ever Chief Revenue Officer.

Key Points: 
  • The all-in-one third-party management platform, Certa , is pleased to announce the addition of Eric Brown as its first-ever Chief Revenue Officer.
  • The news comes on the heels of a $35M Series B announced earlier this month.
  • “With our recent Series B funding round, we are on the fast track to significant growth and expansion,” said Jag Lamba, founder and CEO of Certa.
  • We couldn’t be more excited to have Eric step into this position to drive our go-to-market and revenue generation strategies.”
    "I'm thrilled to join Certa at such an exciting stage of growth,” said Eric Brown.

Certa Raises Oversubscribed $35M Series B to Further Reduce Third-Party Management Friction

Retrieved on: 
Thursday, September 7, 2023

The all-in-one third-party management platform, Certa , today announced it has raised a 2x oversubscribed Series B led by Fin Capital , and Vertex Ventures Southeast Asia and India, with participation from Tru Arrow Partners .

Key Points: 
  • The all-in-one third-party management platform, Certa , today announced it has raised a 2x oversubscribed Series B led by Fin Capital , and Vertex Ventures Southeast Asia and India, with participation from Tru Arrow Partners .
  • This raise brings the total institutional investment in Certa to $50M to date.
  • Certa provides the most comprehensive and intelligent platform for global third-party management across procurement, compliance, ESG, and legal.
  • Since customer feedback is in the company’s DNA, Certa is pioneering the use of advanced Generative AI to streamline third-party ecosystems.